Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its... see more

Recent & Breaking News (NDAQ:NTLA)

Intellia Therapeutics to Present at October Healthcare Investor Conferences

GlobeNewswire September 30, 2019

Arbitration Decision Affirms Intellia Therapeutics' Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

GlobeNewswire September 26, 2019

Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update

GlobeNewswire August 1, 2019

Intellia Therapeutics to Present at August Healthcare Investor Conference

GlobeNewswire July 30, 2019

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update

GlobeNewswire July 25, 2019

Intellia Therapeutics to Participate at June Healthcare Investor Conferences

GlobeNewswire May 30, 2019

Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer

GlobeNewswire May 28, 2019

Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update

GlobeNewswire May 2, 2019

Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy

GlobeNewswire April 29, 2019

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update

GlobeNewswire April 25, 2019

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

GlobeNewswire January 24, 2019

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population

GlobeNewswire December 6, 2018

Intellia Therapeutics to Present at November Healthcare Investor Conferences

GlobeNewswire November 8, 2018

Consolidated Research: 2018 Summary Expectations for STORE Capital, Ares Commercial Real Estate, Intellia Therapeutics, City Office REIT, RealPage, and Data I/O — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 7, 2018

Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments

GlobeNewswire October 31, 2018

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments

GlobeNewswire October 30, 2018

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer

GlobeNewswire October 29, 2018

Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy

GlobeNewswire October 18, 2018

Intellia Therapeutics to Present at October Healthcare Investor Conferences

GlobeNewswire September 24, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

GlobeNewswire September 10, 2018